Chen K, Li Q, Li Y, Jiang D, Chen L, Jiang J
Mol Med Rep. 2024; 30(5).
PMID: 39239742
PMC: 11411235.
DOI: 10.3892/mmr.2024.13324.
Zhang K, Zhu Z, Jia R, Wang N, Shi M, Wang Y
J Exp Clin Cancer Res. 2024; 43(1):160.
PMID: 38840183
PMC: 11155183.
DOI: 10.1186/s13046-024-03082-z.
Shao S, Bu Z, Xiang J, Liu J, Tan R, Sun H
Front Cell Dev Biol. 2024; 12:1343894.
PMID: 38389703
PMC: 10882080.
DOI: 10.3389/fcell.2024.1343894.
Sartorius K, Sartorius B, Winkler C, Chuturgoon A, Shen T, Zhao Y
Int J Mol Sci. 2024; 25(2).
PMID: 38256049
PMC: 10815595.
DOI: 10.3390/ijms25020975.
Ma L, Wu L, Liu S, Zhang X, Luo X, Nawaz S
Sci Rep. 2024; 14(1):224.
PMID: 38168113
PMC: 10762019.
DOI: 10.1038/s41598-023-48760-8.
Exposure to ambient air pollutants, serum miRNA networks, lipid metabolism, and non-alcoholic fatty liver disease in young adults.
Patterson W, Holzhausen E, Chalifour B, Goodrich J, Costello E, Lurmann F
Ecotoxicol Environ Saf. 2023; 264:115486.
PMID: 37729806
PMC: 10548742.
DOI: 10.1016/j.ecoenv.2023.115486.
The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer.
Zhou Y, Dong Y, Zhang A, Wu J, Sun Q
Front Bioeng Biotechnol. 2023; 11:1214190.
PMID: 37662434
PMC: 10470003.
DOI: 10.3389/fbioe.2023.1214190.
miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models.
Callegari E, Guerriero P, Bassi C, DAbundo L, Frassoldati A, Simoni E
Mol Ther Nucleic Acids. 2022; 29:538-549.
PMID: 36035756
PMC: 9395755.
DOI: 10.1016/j.omtn.2022.07.015.
Integrated analysis using ToppMiR uncovers altered miRNA- mRNA regulatory networks in pediatric hepatocellular carcinoma-A pilot study.
Whyte S, Karns R, Min K, Cho J, Lee S, Lake C
Cancer Rep (Hoboken). 2022; 6(1):e1685.
PMID: 35859536
PMC: 9875636.
DOI: 10.1002/cnr2.1685.
MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of .
Ho J, Chen J, Cheuk I, Siu M, Shin V, Kwong A
Am J Transl Res. 2022; 14(3):2021-2036.
PMID: 35422914
PMC: 8991114.
Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.
Sohrabi B, Dayeri B, Zahedi E, Khoshbakht S, Pour N, Ranjbar H
Cancer Gene Ther. 2022; 29(8-9):1105-1116.
PMID: 35082400
DOI: 10.1038/s41417-022-00427-8.
Mesenchymal stem cell-derived exosomes for gastrointestinal cancer.
Zhao L, Zhang K, Shen B, Li J
World J Gastrointest Oncol. 2022; 13(12):1981-1996.
PMID: 35070036
PMC: 8713327.
DOI: 10.4251/wjgo.v13.i12.1981.
Role of Tetraspanins in Hepatocellular Carcinoma.
Cai S, Deng Y, Peng H, Shen J
Front Oncol. 2021; 11:723341.
PMID: 34540692
PMC: 8446639.
DOI: 10.3389/fonc.2021.723341.
Downregulation of miR-199a-3p in Hepatocellular Carcinoma and Its Relevant Molecular Mechanism via GEO, TCGA Database and In Silico Analyses.
Liu A, Pang Y, Chen G, Wu H, He R, Dang Y
Technol Cancer Res Treat. 2020; 19:1533033820979670.
PMID: 33327879
PMC: 7750904.
DOI: 10.1177/1533033820979670.
Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma.
Zhang K, Shao C, Zhu J, Lv X, Tu C, Jiang C
Biosci Rep. 2020; 40(7).
PMID: 32463473
PMC: 7341182.
DOI: 10.1042/BSR20194026.
Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma.
Huang W, Liu A, Cai K, He R, Li Z, Wei Q
Am J Transl Res. 2020; 11(12):7538-7554.
PMID: 31934299
PMC: 6943471.
MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway.
Lou G, Chen L, Xia C, Wang W, Qi J, Li A
J Exp Clin Cancer Res. 2020; 39(1):4.
PMID: 31898515
PMC: 6941283.
DOI: 10.1186/s13046-019-1512-5.
MiR-199a-3p inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via suppressing retinoblastoma 1.
Wangyang Y, Yi L, Wang T, Feng Y, Liu G, Li D
Biosci Rep. 2018; 38(6).
PMID: 30352835
PMC: 6239273.
DOI: 10.1042/BSR20180982.
Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma.
Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A
World J Hepatol. 2018; 10(9):558-570.
PMID: 30310534
PMC: 6177563.
DOI: 10.4254/wjh.v10.i9.558.
TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.
Wang L, Chen C, Feng S, Tian J
Mol Med Rep. 2018; 17(5):7017-7026.
PMID: 29568863
PMC: 5928656.
DOI: 10.3892/mmr.2018.8789.